Form 4: UNITED THERAPEUTICS CEO Sells Shares

Sentiment:

Insider Transaction (Form 4)


Martine A Rothblatt, Chairperson & CEO and a Director of UNITED THERAPEUTICS Corp, sold 9,500 shares of common stock on July 28, 2026.

Summary

  • Option exercise/conversion: acquired 9,500 Common Stock at $135.42 ($1,286,490) on July 28, 2026; holds 333,943 after (Indirect).
  • Open-market sale: disposed of 1,367 Common Stock at $523.15 ($715,152) on July 28, 2026; holds 332,576 after (Indirect).
  • Open-market sale: disposed of 1,074 Common Stock at $524.04 ($562,818) on July 28, 2026; holds 331,502 after (Indirect).
  • Open-market sale: disposed of 876 Common Stock at $525.02 ($459,918) on July 28, 2026; holds 330,626 after (Indirect).
  • Open-market sale: disposed of 1,473 Common Stock at $526.34 ($775,295) on July 28, 2026; holds 329,153 after (Indirect).
  • Open-market sale: disposed of 1,369 Common Stock at $527.16 ($721,678) on July 28, 2026; holds 327,784 after (Indirect).
  • Open-market sale: disposed of 1,149 Common Stock at $528.20 ($606,905) on July 28, 2026; holds 326,635 after (Indirect).
  • Open-market sale: disposed of 625 Common Stock at $529.41 ($330,882) on July 28, 2026; holds 326,010 after (Indirect).
  • Open-market sale: disposed of 1,124 Common Stock at $530.29 ($596,048) on July 28, 2026; holds 324,886 after (Indirect).
  • Open-market sale: disposed of 403 Common Stock at $530.97 ($213,981) on July 28, 2026; holds 324,483 after (Indirect).
  • Open-market sale: disposed of 40 Common Stock at $532.49 ($21,300) on July 28, 2026; holds 324,443 after (Indirect).
  • Option exercise/conversion: disposed of 9,500 Stock Option on July 28, 2026; holds 255,910 after (Indirect).

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $5,003,976 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.

Insider Transactions

Martine A Rothblatt — Director, Officer (Chairperson & CEO)

Transaction made under a Rule 10b5-1 trading plan.

DateTransactionSecuritySharesPriceValueHeld After
2026-07-28Option exercise/conversionCommon Stock9,500$135$1.3M333,943
2026-07-28Open-market saleCommon Stock1,367$523$715.2K332,576
2026-07-28Open-market saleCommon Stock1,074$524$562.8K331,502
2026-07-28Open-market saleCommon Stock876$525$459.9K330,626
2026-07-28Open-market saleCommon Stock1,473$526$775.3K329,153
2026-07-28Open-market saleCommon Stock1,369$527$721.7K327,784
2026-07-28Open-market saleCommon Stock1,149$528$606.9K326,635
2026-07-28Open-market saleCommon Stock625$529$330.9K326,010
2026-07-28Open-market saleCommon Stock1,124$530$596.0K324,886
2026-07-28Open-market saleCommon Stock403$531$214.0K324,483
2026-07-28Open-market saleCommon Stock40$532$21.3K324,443
2026-07-28Option exercise/conversionStock Option9,500——255,910

Key Dates

DateDescription
2026-07-28Option exercise/conversion (9,500 shares)
2026-07-28Open-market sale (1,367 shares)
2026-07-28Open-market sale (1,074 shares)
2026-07-28Open-market sale (876 shares)
2026-07-28Open-market sale (1,473 shares)
2026-07-28Open-market sale (1,369 shares)
2026-07-28Open-market sale (1,149 shares)
2026-07-28Open-market sale (625 shares)
2026-07-28Open-market sale (1,124 shares)
2026-07-28Open-market sale (403 shares)
2026-07-28Open-market sale (40 shares)
2026-07-28Option exercise/conversion (9,500 shares)

Keywords

insider transaction, Form 4, UTHR, UNITED THERAPEUTICS Corp, bearish, Martine A Rothblatt

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.